Search

Displaying results 211 - 220 of 4300 in total
  1. Drug

    Pyrantel

    go.drugbank.com/drugs/DB11156
    ApprovedVet approved

    Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900]. … Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug

  2. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16].

  3. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365]. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.

  4. Drug

    Atropine

    go.drugbank.com/drugs/DB00572
    ApprovedInvestigationalVet approved

    [A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. … Oral atropine is only available in combination products.

  5. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. … It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  6. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer [L1295]. … Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant

  7. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    [L11698] It is available in oral tablets generically and under the brand name ISMO and Monoket. The extended-release forms of the drug are also available generically and under the brand name Imdur. … It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload.

  8. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    [L57979] Carbapenems are the standard treatment for severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary … [L57979,L57980] It retains activity against many extended-spectrum beta-lactamase producers but not against organisms producing serine or metallo-carbapenemases.

  9. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

  10. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    By binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol. … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults